CD274 and neoplasm: Immune checkpoint inhibitors PD-1 antibody and PD-L1 antibody are key drugs for the treatment of driver mutation-free non-small cell lung cancer (NSCLC).1 PD-L1 expressed on tumor cells (TCs) and immune cells (ICs) in tumor tissues assessed with anti-PD-L1 monoclonal SP142 antibody, and on TCs assessed with 22C3 antibody, predicts the therapeutic effectiveness of PD-1 and PD-L1 antibodies.2